Carriers of the mitochondrial mutation m.3243A>G presents highly variable phenotypes including mitochondrial encephalomyopathy, lactoacidosis and stroke-like episodes (MELAS). We 
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1 In addition, carriers may develop diabetes, hearing impairment, cardiomyopathy, migraine, epilepsy, ptosis, and nephropathy. However, the phenotypic heterogeneity is only partially understood.
2,3
The levels of heteroplasmy, that is, the mixture of m.3243A>G
and wildtype m.DNA, contribute to the severity of mitochondrial dysfunction. 4, 5 Cross-sectional studies show negative associations between the heteroplasmy level in leucocytes and the age of onset of diabetes or hearing impairment as well as with the Newcastle Mitochondrial Disease Adult Scale (NMDAS) measures, 6, 7 and a few longitudinal studies report an annual decline in leucocyte heteroplasmy of −0.69 to −1.4 percentage points (pp). [8] [9] [10] The leucocyte mutation burden is lower or undetectable compared to urinary epithelial cell (UEC) and skeletal muscle. 11, 12 Nevertheless, m.3243A>G carriers with low heteroplasmy levels in leucocytes and no previous symptoms are still at risk of developing MELAS 13 or sudden death 14 while others may remain asymptomatic carriers. 6 Consequently, at present it is not possible to predict the individual phenotype or prognosis based solely on mutation load in leucocytes.
Traditionally, m.3243A>G heteroplasmy is quantified by different methods including real-time Polymerase Chain Reaction (PCR) and pyro-sequencing. The introduction of massive parallel sequencing, that is, next generation sequencing (NGS), provides a method for simultaneous detection and quantification of mitochondrial genome-wide heteroplasmies resulting in a higher sensitivity compared to other methods. 15, 16 To extend the knowledge on heteroplasmy and the clinical phenotypes in the m.3243A>G carriers, we conducted a 10-year followup study on changes in leucocyte mutation burden and on development of symptoms during aging.
| MATERIALS AND METHODS

| Heteroplasmy
The participants were recruited from a Danish cohort of 102 individuals identified as carriers of m.3243A>G between March 1995 and July 2014. Among these individuals, a total of 152 blood, 37 muscle, 66 buccal mucosa, and 68 urine samples were collected during this period.
Matched pairs of samples included: leucocytes and UEC (n = 44), leucocytes and buccal mucosa (n = 44), and UEC and buccal mucosa (n = 42). Association of heteroplasmy between skeletal muscle and blood was allowed for with a maximal interval of 3 years between the collections of samples (n = 15). This cohort included 32 subjects from whom paired blood samples were collected at 2 different time-points.
| Clinical presentations
Eight families comprising 46 individuals 17 
| Determination of heteroplasmy level
Total DNA was isolated from peripheral blood leucocytes, buccal mucosa, UEC or skeletal muscle performed with MaxWell16
(Promega, Madison, Wisconsin) according to manufactures protocol.
Level of heteroplasmy was determined using NGS with amplicons adapted from Iliuminas 16S Metagenomic protocol. 18 Primers were designed to amplify the m.3243A>G mutation using forward primer TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGT AAATGATATCATCTCAACTTAG and reverse primer GTCTCGTGGG CTCGGAGATGTGTATAAGAGACAGGATTAGAATGGGTACAATGAGG manually designed according to Illuminas guidelines and designed to avoid amplification of homolog regions in the genome using BLAST. 
| Data analysis
Raw (Single-end, 1 × 100 bp) reads were aligned using BWA-MEM alignment software 19 to the human reference genome (GRCh37). The variant allele frequency and total coverage of the m.3243A>G variant were determined using the bam-readcount tool. 20 Counting the number of C and T nucleotides in the m.3243 position assessed sequencing error-rates. Quality parameters included that samples covered by >100 000X were included.
Eight samples with read coverage <100 000X reads were excluded. 3 | RESULTS
| Statistics
| Methods for analysis of heteroplasmy
The analysis for heteroplasmy levels was validated with 2 standard curves ( Figure S1 Figure S2 ). In addition, 2 null samples were tested with heteroplasmy levels comparable to background noise. Heteroplasmy in 2 null samples and in 2 negative controls (ie, the error rate) ranged from 0.61% to 0.93%. The detection limit was set at 1.5%.
| Heteroplasmy-longitudinal changes in leucocytes
Longitudinal changes in leucocyte heteroplasmy levels were analyzed Table S1 ).
Regression analysis of the annual change in heteroplasmy level with the heteroplasmy level in the initial sample and the age of each individual at the initial sample as independent variables showed a significant negative association with the heteroplasmy level in the initial sample (ρ = −0.92, P < .0001; Figure 1B ), but not with the age. (Data on associations between the heteroplasmy levels of the paired samples, Figure S3) 
| 10-Year clinical follow-up
During the 10-year follow-up of 46 m.3243A>G mutation carriers from 8 families, there were 11 deaths at a median age of 51.7 years (range: 45-83 years; Table 1 ). The causes of death included strokelike episodes (n = 4), congestive heart failure (n = 2), sudden cardiac arrest (n = 1), pulmonary embolism (n = 1), kidney failure (n = 1), and unknown cause of death (n = 2). Patients who developed MELAS, cardiomyopathy or nephropathy presented with UEC m.3243A>G mutation loads higher than 45% (Table S2) .
In 1 family, 2 sisters developed severe cardiomyopathy. The eldest sister died at the age of 45 from congestive heart failure, while her 6 years younger sister had a successful cardiac transplantation at the age of 45 years. In a second family, the brother and his 5 years younger sister developed kidney failure and received kidney transplantation at the age of 49 and 43, respectively (Table S2 ).
| DISCUSSION
The present study represents the largest longitudinal study of change in mutation load of the m.3243A>G mutation in leucocytes, and the first report of the annual rate of decline of mutation burden strongly associates to the level of mutation burden of the initial sample. The annual decline in leucocyte heteroplasmy is in accordance with previous reports [8] [9] [10] . In addition, there was a high mortality rate and progression in the symptoms.
Heteroplasmy in UEC correlate with the levels in skeletal muscle as well as to the clinical phenotype evaluated by the NMDAS. 6, 11, 12 In a recent study by Fayssoil et al. reporting 5.5-year follow-up on 43 m.3243A>G mutation carriers, UEC mutation loads >45% predicted a high risk for major adverse events including stroke. 21 Although our study was not designed to evaluate UEC as a prediction tool, all patients developing MELAS, cardiomyopathy or nephropathy during the follow-up presented with UEC m.3243A>G mutation loads higher than 45% while their leucocyte heteroplasmy levels ranged between 7.2% and 45%. (Table S2) . Consequently, as suggested by the authors' measurement of UEC heteroplasmy may contribute to the identification of individuals at high risk for major adverse events, who may be recommended extended surveillance programs. Still, quantification of UEC mutation burden is not a strong prediction tool for the development of the individual m.3243A>G phenotype. Therefore, it is still difficult to provide the m.3243A>G carriers including women who plan to conceive precise counseling about disease manifestations.
In 2 families, we noticed strikingly similar, but less frequently reported phenotypes among siblings who developed cardiomyopathy and nephropathy, respectively. A previous study reported on post-mortem findings in 2 monozygotic twins both presenting with MELAS phenotypes as well as similar levels of heteroplasmy in all tissues. 22 Albeit speculative and based on only few observations, this may suggest some degree of clustering of symptoms within families. However, larger follow-up studies are needed to clarify whether some m.3243A>G families present with a "family-specific" In conclusion, the longitudinal study on m.3243A>G leucocyte mutation burden assessed by NGS shows declining levels, and the annual change associates with the level of the initial sample. In addition, in the 10-year follow-up there was a high mortality.
